Literature DB >> 3063476

Cefuroxime axetil.

M A Marx1, W K Fant.   

Abstract

Cefuroxime axetil is a orally active prodrug formulation of cefuroxime, which upon absorption undergoes immediate deesterification to free cefuroxime. Cefuroxime axetil offers an in vitro antibacterial spectrum against many gram-positive and some gram-negative organisms. Its beta-lactamase stability makes it useful in treating a variety of infections caused by beta-lactamase-producing strains of Haemophilus influenzae, Branhamella catarrhalis, and Staphylococcus aureus. Cefuroxime axetil has good activity against the Enterobacteriaceae and moderate activity against non-Bacteroides fragilis anaerobes. Clinical studies suggest it is at least as effective as ampicillin, amoxicillin, amoxicillin/clavulanic acid, penicillin V, or cefaclor in the treatment of uncomplicated urinary tract infections, acute otitis media, upper respiratory infections, skin and soft tissue infections, and uncomplicated gonorrhea.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063476     DOI: 10.1177/106002808802200901

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  3 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans.

Authors:  S W Luger; P Paparone; G P Wormser; R B Nadelman; E Grunwaldt; G Gomez; M Wisniewski; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

3.  Killing kinetics of cefuroxime against Streptococcus pneumoniae in an in vitro model simulating serum concentration profiles after intramuscular administration.

Authors:  E Bingen; C Doit; R Farinotti; N Lambert-Zechovsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.